Growth effects of raloxifene, estradiol, medroxy-progesterone acetate, and progesterone on human endometrial adenocarcinoma cells [4]

Fertility and Sterility

Volumn 79, Issue 1, 2003, Pages 223-225

  Boostanfar, Robert ^a,b   Amezcua, Charles A ^b   Tourgeman, David E ^b   Roy, Subir ^b   Felix, Juan C ^b   Stanczyk, Frank Z ^b  

^a WOMEN S AND CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

CARCINOMA CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG MEGADOSE; ENDOMETRIUM CARCINOMA; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LETTER; LOW DRUG DOSE; MEASUREMENT; MENOPAUSAL SYNDROME; MODEL; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0037229844     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(02)04409-6     Document Type: Article

References (12)

1. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal. N Engl J Med. 337:1997;1641-1647.
2. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3 year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators . JAMA. 282:1999;637-645.
3. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 279:1998;1445-1451.
4. Poulin R., Merand Y., Poirier D., Levesque C., Dufour J.M., Labrie F. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat. 14:1989;65-76.
5. Gottardis M.M., Jordan V.C. Antitumor actions of keoxifene and tamoxifen in the N-nitromethlurea-induced rat mammary carcinoma model. Cancer Res. 47:1987;4020-4024.
6. Systemic treatment N-nitromethylurea of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339:1992;1-15.
7. Cohen F., Watts S., Shah A., Akers R., Plouffe L. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol. 95:2000;104-110.
8. Gottardis M.M., Ricchio M.E., Satyaswaroop P.G., Jordan V.C. Effect of steroidal and nonsteroidal anti-estrogens on the growth of a tamoxifen stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res. 50:1990;3189-3192.
9. American College of Obstetricians and Gynecologists Committee Opinion. Hormone Replacement Therapy in Women Treated for Endometrial Cancer. No. 235. May 2000. The American College of Obstetricians and Gynecologists. Washington, DC.
10. Mosmann T. Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays . J Immunol Methods. 65:1983;55-63.
11. Simard J., Sanchez R., Poirier D., Gauthier S., Singh S.M., Merand Y., et al. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res. 57:1997;3494-3497.
12. Suriano K., McHale M., McLaren C., Kuo-Tung L., Re A., DiSaia P.J. Estrogen replacement therapy in endometrial cancer patients a matched control study . Obstet Gynecol. 97:2001;555-560.